H.B. Fuller heads into its September 23 earnings print with a painful month behind it and a widening gap between where the stock trades and where analysts think it belongs.
The price tells the sharpest story. FUL closed at $50.89 on Tuesday, down 19% over the past month and off 4% for the week — a sharper decline than most of its specialty chemicals peers. AVNT shed roughly 3.8% on the week and PPG fell 4.4%, so the sector is broadly soft. But AXTA led the group lower at -6.3% while more resilient names like IOSP and dropped only 1.6-1.7%, suggesting the selloff in Fuller is running hotter than the sector average warrants.
Short positioning has climbed meaningfully, but the borrow market is sending a different signal. Short interest reached 5.25% of the free float — up 33% over the past month — as the stock fell. That is a real move, not noise, and it points to bears adding conviction into the weakness. Yet the lending market is not stressed: availability remains extremely loose at 2,030%, near the highest level of the past year, and the cost to borrow is just 0.45%. When availability is that wide, there is no mechanical pressure on shorts. The borrow is cheap and plentiful. Options positioning is similarly relaxed. The put/call ratio ticked up to 0.077 on Monday — fractionally above its 20-day average of 0.068 and barely a quarter of a standard deviation from normal. The options market is not bracing for anything dramatic.
What makes this week's setup striking is the gap between price and street opinion. The analyst consensus mean target is $73.29, implying roughly 44% upside from current levels. The most recent analyst actions — from late June — were uniformly constructive: Citigroup raised its target to $75, Deutsche Bank to $72, and JP Morgan upgraded to Overweight with a $67 target. Those moves are now nearly three months old, and the stock has fallen significantly since. Whether any of those targets hold into next week's print is the core question. On valuation, the compression is visible: the P/E multiple dropped from around 12.2x thirty days ago to 9.8x today, and price-to-book has fallen by more than 0.28x over the same period to just 1.18x. The EV/EBIT factor score ranks in the 65th percentile — reasonable for a specialty chemicals name — but the short score of 41 sits in the bottom quarter of its universe, reflecting the combination of price pressure and rising short interest.
The insider register adds a muted footnote. The 90-day net position is a sale of 9,561 shares worth roughly $593,000, driven by a single exercise-and-sell by an Executive VP in August. That pattern — option exercise followed by immediate sale — is a compensation mechanic rather than a bearish signal. The most directionally meaningful insider action remains CEO Celeste Beeks Mastin's open-market purchase of 5,170 shares at $57.08 in April, which now sits underwater.
H.B. Fuller's last two earnings prints produced a -2.1% and -9.1% five-day move respectively, so the stock has punished bulls who held through results. With the next print on September 23, the key question is whether the month-long selloff has already priced in whatever disappointment the market feared — or whether the bears who built positions through August and early September are positioned for a fresh catalyst to confirm the trade.
See the live data behind this article on ORTEX.
Open FUL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
